These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 16731025)

  • 21. Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function.
    Iyer SS; Morgan JC; Sethi KD
    Neurology; 2005 Nov; 65(9):1507. PubMed ID: 16275853
    [No Abstract]   [Full Text] [Related]  

  • 22. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
    Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
    Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Intravenous infusion of L-dopa: current prospective therapies].
    Peppe A; De Angelis D; Tolli VS; Rizzo PA; Scoppetta C
    Riv Neurol; 1991; 61(5):197-200. PubMed ID: 1808680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Usefulness of increasing the proportion of carbidopa to levodopa in the long-term treatment of Parkinson's disease].
    Bermejo Pareja F; Martínez-Martín P
    Med Clin (Barc); 1984 Feb; 82(7):305-10. PubMed ID: 6717135
    [No Abstract]   [Full Text] [Related]  

  • 25. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 27. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
    Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
    Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical studies with levodopa/carbidopa intestinal gel].
    Klivényi P; Vécsei L
    Ideggyogy Sz; 2014 Jan; 67(1-2):5-8. PubMed ID: 24654442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P; Fasano A; Cannas A; Mulas CS; Marrosu MG; Lang AE; Marrosu F
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Intraduodenal infusion of levodopa].
    Valldeoriola F; Cámara A
    Rev Neurol; 2010 Jul; 51(1):41-8. PubMed ID: 20568067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levodopa-carbidopa intrajejunal gel in advanced Parkinson disease with "on" freezing of gait.
    Cossu G; Ricchi V; Pilleri M; Mancini F; Murgia D; Ricchieri G; Mereu A; Melis M; Antonini A
    Neurol Sci; 2015 Sep; 36(9):1683-6. PubMed ID: 25939726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nyholm D; Jansson R; Willows T; Remahl IN
    Neurology; 2005 Nov; 65(9):1506-7. PubMed ID: 16275852
    [No Abstract]   [Full Text] [Related]  

  • 35. Duodopa infusion treatment: a point of view from the gastroenterologist.
    Negreanu L; Popescu BO; Babiuc RD; Ene A; Bajenaru OA; Smarandache GC
    J Gastrointestin Liver Dis; 2011 Sep; 20(3):325-7. PubMed ID: 21961105
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: preliminary findings.
    Maricle RA; Nutt JG; Carter JH
    Mov Disord; 1995 May; 10(3):329-32. PubMed ID: 7651451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Greater motor improvement in right hemibody Parkinson's patients after dopaminergic medications.
    Foster PS; Drago V; Skidmore F; Skoblar BM; Crucian GP; Heilman KM
    Parkinsonism Relat Disord; 2009 Jan; 15(1):20-3. PubMed ID: 18387842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Duodenal levodopa/carbidopa infusion therapy in patients with advanced Parkinson's disease leads to improvement in caregivers' stress and burden.
    Santos-García D; Añón MJ; Fuster-Sanjurjo L; de la Fuente-Fernández R
    Eur J Neurol; 2012 Sep; 19(9):1261-5. PubMed ID: 22248261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Perioperative management of a patient with Parkinson's disease with intravenous infusion of levodopa].
    Mizuno J; Kato S; Watada M; Morita S
    Masui; 2009 Oct; 58(10):1286-9. PubMed ID: 19860235
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.